Jagdeesh Ullal1, Joseph A Aloi2. 1. Center for Diabetes and Endocrinology, Division of Endocrinology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. ullalj@upmc.edu. 2. Department of Internal Medicine, Section on Endocrinology and Metabolism, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Abstract
PURPOSE OF REVIEW: The goal of this review is to summarize information about insulin dosing software and calculators used as computerized decision support systems or electronic glucose management systems (eGMS). These are used for hospitalized, insulin-treated patients with diabetes. We describe the advantages and disadvantages and the rationale for their use. RECENT FINDINGS: We compared commercially available insulin dosing software, namely, Glucommander™, EndoTool®, GlucoStabilizer®, and GlucoTab®, in addition to computerized order entry systems that are available in electronic health records. The common feature among these eGMS is their ability to limit occurrences of hypoglycemia while achieving and maintaining patients at target blood glucose level. More research needs to be done examining the efficacy of eGMS in disease-specific states and their benefits and utility in preventing adverse outcomes. Their long-term benefits to health care systems are beginning to emerge in cost-saving benefits and prevention of readmissions.
PURPOSE OF REVIEW: The goal of this review is to summarize information about insulin dosing software and calculators used as computerized decision support systems or electronic glucose management systems (eGMS). These are used for hospitalized, insulin-treated patients with diabetes. We describe the advantages and disadvantages and the rationale for their use. RECENT FINDINGS: We compared commercially available insulin dosing software, namely, Glucommander™, EndoTool®, GlucoStabilizer®, and GlucoTab®, in addition to computerized order entry systems that are available in electronic health records. The common feature among these eGMS is their ability to limit occurrences of hypoglycemia while achieving and maintaining patients at target blood glucose level. More research needs to be done examining the efficacy of eGMS in disease-specific states and their benefits and utility in preventing adverse outcomes. Their long-term benefits to health care systems are beginning to emerge in cost-saving benefits and prevention of readmissions.
Authors: Annette Moxey; Jane Robertson; David Newby; Isla Hains; Margaret Williamson; Sallie-Anne Pearson Journal: J Am Med Inform Assoc Date: 2010 Jan-Feb Impact factor: 4.497
Authors: Dorin T Colibaseanu; Osayande Osagiede; Rozalina G McCoy; Aaron C Spaulding; Elizabeth B Habermann; James M Naessens; Michelle F Perry; Launia J White; Robert R Cima Journal: Endocr Pract Date: 2018-10-05 Impact factor: 3.443
Authors: Guillermo E Umpierrez; Dawn Smiley; Ariel Zisman; Luz M Prieto; Andres Palacio; Miguel Ceron; Alvaro Puig; Roberto Mejia Journal: Diabetes Care Date: 2007-05-18 Impact factor: 19.112
Authors: Etie S Moghissi; Mary T Korytkowski; Monica DiNardo; Daniel Einhorn; Richard Hellman; Irl B Hirsch; Silvio E Inzucchi; Faramarz Ismail-Beigi; M Sue Kirkman; Guillermo E Umpierrez Journal: Diabetes Care Date: 2009-05-08 Impact factor: 19.112
Authors: Sallie-Anne Pearson; Annette Moxey; Jane Robertson; Isla Hains; Margaret Williamson; James Reeve; David Newby Journal: BMC Health Serv Res Date: 2009-08-28 Impact factor: 2.655
Authors: William B Horton; Andrew J Barros; Robert T Andris; Matthew T Clark; J Randall Moorman Journal: Crit Care Med Date: 2022-03-01 Impact factor: 7.598